Posted by Michael Wonder on 18 Aug 2022
EMA starts review of conditional marketing authorisation application for Skycovion COVID-19 vaccine
18 August 2022 - The EMA’s CHMP has started a review of a conditional marketing authorisation application for Skycovion, a vaccine for protecting against COVID-19.
The applicant, SK Chemicals, has submitted data on how well the vaccine triggers the production of antibodies against the original strain of SARS-CoV-2, the virus that causes COVID-19. The company also submitted data on the safety and quality of the vaccine.
